study on the protective effect of the Mixture of Shengmai Powder and Danshen Decoction (生脉散丹参饮合剂) on the myocardium of diabetic cardiomyopathy in the rat model

Objective  

To study the protective effect of the Mixture of Shengmai Powder and Danshen Decoction (生脉散丹参饮合剂, abbreviated as the Mixture) in the rat model with type 2 diabetic cardiomyopathy in the rat model with type 2 diabetic cardiomyopathy, abbreviated as the Mixture) in the rat model with type 2 diabetic cardiomyopathy (DCM).     

总责任护士负责制整体干预在绒毛膜癌患者中的护理效果观察

观察总责任护士负责制整体干预在绒毛膜癌患者中的护理效果。方法 选取2017年6月—2020年6月河南某医院收治的绒毛膜癌患者85例设为观察组，另选取该院同期收治的采用常规护理干预的绒毛膜癌患者71例设为对照组。对比2组患者干预前后心理状况、生活质量、营养水平及依从性。结果 干预后，2组患者焦虑自评量表（SAS）和抑郁自评量表（SDS）评分均低于干预前（均P＜0.05），且观察组得分明显低于对照组（均P＜0.05）。干预后，观察组患者心理状态、疼痛、饮食、自理能力、对治疗的态度、对疾病的认知评分均高于对照组（均P＜0.05）。干预后，观察组血红蛋白（Hb）、血清白蛋白（Alb）、前白蛋白（PAB）、转铁蛋白（TRF）水平均高于对照组（均P＜0.05）。观察组患者依从性为94.12%，高于对照组的77.46%（P＜0.05）。结论 总责任护士负责制整体干预在绒毛膜癌患者中的护理效果较好，可缓解患者不良情绪，提高其生活质量和营养水平，临床推广价值较高。     

Study on the Protective Effect of Shengmai San(生脉散) on the Myocardium in the Type 2 Diabetic Cardiomyopathy Model Rat

Objective:To study the effect of Shengmai San(生脉散Pulse-activating Powder) in protecting myocardium in the rat of the type 2 diabetic cardiomyopathy(DCM) model.Methods:The DCM rat model was established by combination of insulin resistance induced by a high-fat diet with intraperitoneal injection of high dose streptozotocin(50 mg/kg).And these rat models were randomly divided into three groups:a normal group(n=12,one of them died),a model group(n=15) and a Shengmai San group(treatment group,n=15).The damage of the myocardium was assessed by electrocardiogram at the twelfth week after modeling,and the blood glucose,cholesterol and triglyceride levels were determined;the content of the left cardiac ventricle myocardial collagen was quantified by Masson staining test;the level of myocardial cell apoptosis was detected with TUNEL apoptosis detection kit;the damage extent of the myocardial sub-cellular structures was observed by electron microscopy;the expression levels of cardiac TSP-1(Thrombospondin-1),TGF-β1(Transforming Growth Ffactor-β) and TRB-3(Tribbles homolog 3) proteins were detected by immunohistochemical method;the expression levels of cardiac TSP-1,A-TGF-β1 and L-TGF-β1 proteins were detected by Western blotting;and the expression levels of TSP-1 and TRB-3 mRNAs were detected by real-time quantitative PCR.Results:Compared with the control group,the blood glucose,cholesterol,triglycerides levels in both the model groups and the Shengmai San group were significantly decreased;the myocardial tissue was less damaged and the collagen content was reduced in the Shengmai San group;the myocardial sub-cellular structure was injured to a lesser extent;the expression levels of myocardial TSP-1,TGF-β1,TRB-3,and TSP-1,A-TGF-β1,L-TGF-β1 and chymase were decreased,and the expression levels of TSP-1 mRNA and TRB-3 mRNA were decreased in both the model groups and the Shengmai San group(the latter was better),.Conclusion:Shengmai San can inhibit myocardial fibrosis in the rat of diabetic cardiomyopathy,and significantly delay the formation of diabetic cardiomyopathy in hyperglycemia rats through multiple pathways.     

参麦注射液联合血栓通注射液治疗冠心病心绞痛42例

目的:观察参麦注射液联合血栓通注射液治疗冠心病心绞痛的临床疗效.方法:将82例本科室门诊收治的冠心病患者按随机数字表法随机分为两组.两组均以阿司匹林肠溶片100 mg,1d1次,睡前顿服;倍他乐克100 mg,1d2次,早晚分服;螺内酯10 mg,1d2次,口服;西地兰0.5 mg,1d1次,口服为基本药物.对照组40例在基本药物的基础上合复方丹参注射液20 mL(2 mL×10支)加镁极化液500 mL,静脉输注.治疗组42例在基本药物的基础上加参麦注射液(0.25 g×2支)合血栓通注射液(250 mL),联合治疗判定两组均1d1次,14 d为1个疗程,1个疗程后观察疗效.结果:两组治疗前后心绞痛症状疗效对比,差别有统计学意义(P＜0.05);心电图疗效对比,差别有统计学意义(P＜0.01).结论:参麦注射液联合血栓通注射液治疗冠心病心绞痛,疗效确切.     

血府逐瘀汤对大鼠糖尿病性心肌病的影响

目的: 观察2型糖尿病心肌病大鼠心肌组织的病理改变以及血府逐瘀汤对于糖尿病性心肌病的治疗作用,探讨心肌病发生的病理机制。方法: 雄性Wistar大鼠42只,采用高脂高热量饮食诱导出胰岛素抵抗,加单次中等剂量(50 mg/kg)链脲佐菌素腹腔注射建立糖尿病动物模型。8周后采用心电图及超声心动图评价心肌受损情况;取血检测血糖、胆固醇、甘油三酯含量;心肌组织Masson染色定量左室心肌胶原纤维;TUNEL凋亡试剂盒检测心肌细胞凋亡,光镜和电镜观察心肌细胞结构破坏程度。结果: 与相同时点正常组比较,模型组血糖、甘油三酯、胆固醇含量升高(P<0.05),第11、14周左室收缩末期内径明显增厚(P<0.01),第14周左室舒张末期内径增厚(P<0.05),心肌组织结构破坏严重,胶原纤维含量增多(P<0.01),细胞凋亡增多;与相同时点模型组相比,血府逐瘀汤组大鼠血糖、胆固醇、甘油三酯明显降低(P<0.05),第11周左室收缩末期内径、第14周左室舒张末期内径增厚减低(P<0.05),第14周左室重量明显变轻(P<0.01),心肌组织破坏程度较轻,胶原纤维含量显著减少(P<0.01),心肌细胞亚细胞结构破坏程度较轻,细胞凋亡减少。结论: 糖尿病性心肌病时,血糖、胆固醇和甘油三酯含量升高,心肌增厚,心肌组织内胶原纤维含量增多,结构破坏严重,细胞凋亡增多;血府逐瘀汤能够降低糖尿病心肌病时血糖、胆固醇和甘油三酯水平,减轻心肌纤维化的病理改变程度,延缓糖尿病导致的心肌病进程。     

补肾阴、补气、活血中药方对骨髓抑制小鼠脾脏促血小板生成素mRNA、促血小板生成素受体mRNA及转录因子GATA-1 mRNA的影响

目的：进一步研究补肾阴、补气、活血中药方对骨髓抑制小鼠保护的作用机制。方法：使用实时荧光定量RT-PCR检测小鼠脾脏促血小板生成素（thrombopoietin,TPO） mRNA、促血小板生成素受体（c-Mpl）mRNA及转录因子GATA-1 mRNA表达水平。结果：六味地黄汤、补中益气汤均能明显升高骨髓抑制小鼠TPO、c-Mpl及GATA-1 mRNA的表达。复方丹参饮能对小鼠脾脏TPO、c-Mpl及GATA-1 mRNA表达影响不明显。结论：六味地黄汤、补中益气汤均能通过升高骨髓抑制小鼠TPO、c-Mpl及GATA-1 mRNA的表达水平从而促进骨髓抑制小鼠的外周血恢复。     

六味地黄汤、补中益气汤、复方丹参饮对骨髓抑制小鼠保护的作用机制

目的 :进一步研究补肾阴、补气、活血中药方对骨髓抑制小鼠保护的作用机制。 方法 :使用实时荧光定量RT-PCR检测小鼠脾脏促血小板生成素(thrombopoietin,TPO) mRNA、促血小板生成素受体(c-Mpl)mRNA及转录因子GATA-1 mRNA表达水平。 结果 :六味地黄汤、补中益气汤均能明显升高骨髓抑制小鼠TPO,c-Mpl及GATA-1 mRNA的表达。复方丹参饮对小鼠脾脏TPO,c-Mpl及GATA-1 mRNA表达影响不明显。 结论 :六味地黄汤、补中益气汤均能通过升高骨髓抑制小鼠TPO,c-Mpl及GATA-1 mRNA的表达水平从而促进骨髓抑制小鼠的外周血恢复。     

RALOX方案与FOLFOX4 方案在中晚期原发肝癌患者中的应用效果比较

目的:对比雷替曲塞+奥沙利铂(Raltitrexed+Oxaliplatin,RALOX)与氟尿嘧啶+亚叶酸钙+奥沙利铂(Fluorouracil+Calcium folinate+Oxaliplatin,FOLFOX4)在中晚期原发肝癌(Primary liver cancer,PLC)患者中的应用价值.方法:将112例中晚期PLC患者随机分为研究组及对照组,各56例.给予研究组RALOX方案治疗,给予对照组FOLFOX4方案治疗.比较两组甲胎蛋白(Alpha-fetoprotein,AFP)水平、生存情况(1年生存率(Survival rate,SR)、中位生存期(Median overall survival,mOS)、中位无进展生存期(Median progression—free survival,mPFS))及毒副反应.结果:治疗后,研究组AFP水平低于对照组,mOS、mPFS均长于对照组,消化道反应、肾毒性、心脏毒性、心脏毒性、神经毒性发生率低于对照组(P<0.05).结论:与FOLFOX4方案相比,RALOX方案治疗中晚期PLC患者能降低AFP水平,促进病情缓解,且能降低部分毒副反应发生风险,延长患者生存期.     

中药复方联合介入方法治疗原发性肝癌27例

目的观察以奥沙利铂（L-OHP）为主的肝动脉化疗栓塞介入治疗配合中医药辨证分型治疗中晚期肝癌的临床疗效及价值。方法 54例中晚期肝癌患者随机分为治疗组和对照组,对照组单纯应用以L-OHP为主肝动脉化疗栓塞介入治疗,治疗组应用以L-OHP为主肝动脉化疗栓塞介入治疗配合中医辨证治疗,观察两组在治疗前后瘤体大小、症状改善、癌胚抗原水平及治疗后不良反应有无差异。结果两组在症状改善及治疗后不良反应差异有显著性,治疗前后瘤体大小及癌胚抗原水平无显著差异。结论中药联合介入治疗原发性肝癌能减轻患者治疗后不良反应,提高患者生存质量。